Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.
Zhou T, Damsky W, Weizman OE, McGeary MK, Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, Sanmamed MF, Bosenberg MW, Ring AM. Zhou T, et al. Among authors: sanmamed mf. Nature. 2020 Jul;583(7817):609-614. doi: 10.1038/s41586-020-2422-6. Epub 2020 Jun 24. Nature. 2020. PMID: 32581358 Free PMC article.
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors.
Melero I, Tanos T, Bustamante M, Sanmamed MF, Calvo E, Moreno I, Moreno V, Hernandez T, Martinez Garcia M, Rodriguez-Vida A, Tabernero J, Azaro A, Ponz-Sarvisé M, Spanggaard I, Rohrberg K, Guarin E, Nüesch E, Davydov II, Ooi C, Duarte J, Chesne E, McIntyre C, Ceppi M, Cañamero M, Krieter O. Melero I, et al. Among authors: sanmamed mf. Sci Transl Med. 2023 May 10;15(695):eabp9229. doi: 10.1126/scitranslmed.abp9229. Epub 2023 May 10. Sci Transl Med. 2023. PMID: 37163618
Reply to letter to the editor "Bureaucracy or Streamlining the Rules in "Good Clinical Practice (GCP)" - Has Equipoise Occurred?" by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna.
Perez-Gracia JL, Penel N, Calvo E, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF. Perez-Gracia JL, et al. Among authors: sanmamed mf. Ann Oncol. 2023 May;34(5):498-499. doi: 10.1016/j.annonc.2023.02.003. Ann Oncol. 2023. PMID: 37121610 Free article. No abstract available.
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.
Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA. Gettinger SN, et al. Among authors: sanmamed mf. Nat Commun. 2018 Aug 10;9(1):3196. doi: 10.1038/s41467-018-05032-8. Nat Commun. 2018. PMID: 30097571 Free PMC article.
Cytokines in clinical cancer immunotherapy.
Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I. Berraondo P, et al. Among authors: sanmamed mf. Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9. Br J Cancer. 2019. PMID: 30413827 Free PMC article. Review.
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L. Wang J, et al. Among authors: sanmamed mf. Cell. 2019 Jan 10;176(1-2):334-347.e12. doi: 10.1016/j.cell.2018.11.010. Epub 2018 Dec 20. Cell. 2019. PMID: 30580966 Free PMC article.
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.
Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I. Schalper KA, et al. Among authors: sanmamed mf. Nat Med. 2019 Mar;25(3):470-476. doi: 10.1038/s41591-018-0339-5. Epub 2019 Feb 11. Nat Med. 2019. PMID: 30742120 Clinical Trial.
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.
Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O'Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L. Wang J, et al. Among authors: sanmamed mf. Nat Med. 2019 Apr;25(4):656-666. doi: 10.1038/s41591-019-0374-x. Epub 2019 Mar 4. Nat Med. 2019. PMID: 30833750 Free PMC article.
102 results